NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Elysian Wealth Fund | 2.87% |
| Krishnamurthy C G | 1.62% |
| Suvi Rubber Pvt Ltd | 1.52% |
| Shree Salasar Properties and Finance Private Limited | 1.49% |
| Chetan Kirtibhai Mehta | 1.30% |
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 AAREY DRUGS & PHARMACEUTICALS LTD – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Revenue from Operations (Q1 FY27): Rs 4,462.55 lakhs vs Rs 10,220.83 lak | 2026-08-14 |
| Quarterly results · Q4 FY26 AAREY DRUGS & PHARMACEUTICALS LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Total Assets (as of 31st March 2026): ₹21,124.17 lakhs (previous year 3 | 2026-05-30 |
| Quarterly results | 2026-05-11 |
| Quarterly results · Q3 FY26 AAREY DRUGS & PHARMACEUTICALS LIMITED - DOCUMENT SUMMARY HEADLINE NUMBERS • Company approved unaudited financial results for Q3 ended 31st December | 2026-02-11 |
| Quarterly results · Q2 FY26 AAREY DRUGS & PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY H1 FY2025-26 (Half Year Ended September 30, 2025) --- HEADLINE NUMBERS • Revenue from Ope | 2025-11-13 |
| Annual report FY2025 AAREY DRUGS & PHARMACEUTICALS LIMITED – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹47,394.33 lakhs (FY25) vs ₹39,561 | 2025-09-06 |
| Quarterly results · Q1 FY26 AAREY DRUGS & PHARMACEUTICALS LIMITED – Q1 FY2025-26 RESULTS SUMMARY HEADLINE NUMBERS • Revenue from Operations Q1 FY26: Rs. 1,022.83 lakhs (vs. Rs. | 2025-08-13 |
| Quarterly results | 2025-02-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aarey Drugs & Pharmaceuticals Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.